![Richard Angell](https://profiles-cardiff.imgix.net/attachments/20?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Richard Angell
Senior Research Fellow
School of Biosciences
- AngellR@cardiff.ac.uk
- +44 29225 11094
- Main Building, Park Place, Cardiff, CF10 3AT
Overview
Richard Angell is an experienced drug discovery scientist. He led early stage drug discovery at Arrow Therapeutics, an antiviral drug discovery company, which was sold to AstraZeneca in 2007 for $150M. He was a founder of Reviral, a named inventor on patents supporting RV521 and a consulting medicinal chemist for the company. Reviral was sold to Pfizer in 2022 for $525M. During the coronavirus pandemic he co-founded 3C (an antiviral drug discovery company focused on pandemic preparedness). He was head of the Drug Discovery Group, UCL, (2012-2019) where he built novel drug discovery projects that were subsequently partnered with biotech & venture funds. Since 2020 he has been Commercialisation Lead, MDI, where he led the partnering of 1 project with a South Korean biotech company.
Publication
2024
- Ahmed, A. A. et al. 2024. Structure–activity relationships for the G-quadruplex-targeting experimental drug QN-302 and two analogues probed with comparative transcriptome profiling and molecular modeling. Scientific Reports 14(1), article number: 3447. (10.1038/s41598-024-54080-2)
Articles
- Ahmed, A. A. et al. 2024. Structure–activity relationships for the G-quadruplex-targeting experimental drug QN-302 and two analogues probed with comparative transcriptome profiling and molecular modeling. Scientific Reports 14(1), article number: 3447. (10.1038/s41598-024-54080-2)